Blog Layout

Non-Traditional Pain Management

September 3, 2023

This document is for informational and educational purposes only and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified health care provider.  All information contained in this document is protected by copyright and remains the property of ProCare HospiceCare.  All rights reserved.


Pain is a common and debilitating symptom experienced in our hospice and palliative care patients.

There are three distinct types of pain, including:

  • Nociceptive: Localized, consistent pain; tissue damage/ inflammation
  • Neuropathic: Caused by nerve damage; follows nerve pathways; described as episodic numbness, tingling, burning or stabbing pain
  • Nociplastic: Centralized and widespread pain syndrome; chronic overlapping type pain conditions (ie fibromyalgia)


Nociplastic pain is a more recently utilized term. The International Association for the Study of Pain (IASP) officially adopted the term in 2018 as a “third mechanistic descriptor” of chronic pain to “more fully characterize the known pathophysiological mechanisms of pain.” 


There are several reasons why clinicians and patients or their family members steer toward the non-traditional/alternative medicine route vs. the standard of care for pain management (medications including opioids, NSAIDs or acetaminophen). These reasons include adverse reactions (drowsiness is typically number one, followed by constipation and nausea), safety concerns (fall risk), the fear factor (morphine in particular), lack of efficacy (despite escalating doses), abuse/misuse, and overall patient preference.


There are several therapy types available for non-traditional pain management:


Medication Therapies
If the patient/family is hesitant to try opioids or increase the dose of their current opioid regimen, potential adjuvant medications for neuropathic pain include gabapentin and antidepressants such as amitriptyline, nortriptyline, venlafaxine or pregabalin (Lyrica®). These medications are effective for nerve pain; however, they carry the risk for adverse effects such as drowsiness.


Methadone is an alternative opioid that is long acting and may help with both nociceptive and neuropathic pain due to its distinctive mu opioid agonist activity. Methadone is a synthetic opioid that is in the phenyl-heptylamine class of opioids (separate from morphine), which makes it safe to use with morphine allergies and tolerated better than traditional opioids.

Natural Therapies


Cannabis
Medical Marijuana and Cannabis have a rich and controversial history. The endocannabinoid system within the body regulates the synaptic neurotransmission and is comprised of two cannabinoid receptors, CB1 (brain and CNS) and CB2 (peripheral organs/immune system). CBI receptors have a similar neurochemical and pharmacological characteristics to opioid receptors and cannabis’ analgesic effects may be mediated at the spinal cord. It has been proven effective in refractory neuropathic pain and pain associated with Multiple Sclerosis and various cancers. In studies, cannabis is significantly better than placebo, but comparable to codeine. The greatest benefits may be seen in neuropathic pain and as an adjunct to other long-acting pain regimens. Cannabis products are available in a variety of products and routes of administration, inhalation and oral routes are the most commonly used.

There are several notable adverse effects of cannabis use including, but not limited to: euphoria, sedation, psychosis, memory loss, hallucinations, appetite changes (could be a positive), sleep disturbances and dry mouth. Even though cannabis has become more popular in the last few years, it is still a Schedule I controlled substance (CI) federally. Due to this CI status, it cannot be prescribed legally by a physician and is subject to state-specific regulations at this time. To view your state-specific cannabis laws, visit the National Conference of State Legislature (NCSL) website at https://www.ncsl.org/health/state-medical-cannabis-laws. Keeping your state-specific laws in mind, it is best as a hospice clinician to document that your patient intends to use cannabis and provide them with evidenced-based resources to encourage safe use.


Aromatherapy

  • Essential oils are FDA classified as “cosmetics”
  • Knowledge is key to proper use for patient, family, and nurse
  • Safety concerns: toxicity (oral or inhaled), chemical burns, flammability
  • Potential benefits for hospice/palliative care
  • Pain Management
  • Nausea/Vomiting
  • Anxiety/Stress
  • Insomnia


Integrative Therapies

  • Meditation
  • Most studied technique = Mindfulness-based stress reduction (MBSR)
  • Generally safe with no reported adverse effects
  • Mental activity can influence physiologic function
  • Not specifically helpful for pain, but showed promise for emotional wellbeing, anxiety, depression, and stress
  • Massage Therapy
  • Swedish massage using specific strokes used most often in cancer patients
  • Also reflexology, deep tissue massage, shiatsu
  • Studies show modest improvement in pain scores
  • Safety concerns (use a trained massage therapist): Avoid pressure around tumor or bone metastases sites; implanted pumps, areas of wound or skin breakdown, sensitive skin after radiation
  • Acupuncture
  • Founded from Traditional Chinese Medicine practices
  • Method: Use of filiform needles inserted on body in specific areas and stimulated with manual manipulation (twist, pull, or push), heat or electrical pulses
  • Systematic reviews show a significant reduction in pain intensity of acute/chronic low back pain vs. placebo
  • Cancer pain: equivalent or superior to oral pain medications
  • Safety concerns: Pain/bleeding during needling


Based on the best available evidence, refractory pain is best managed with a combination of pharmacological and non-pharmacological type therapies. Adverse reactions and side effects can limit use of opioid or adjuvants for pain management. It is important to respect individual patient values and find that delicate balance between traditional medicine and complementary methods to achieve patient-centered care at end of life.


References

Zeng YS, Wang C, Ward KE, Hume AL. Complementary and Alternative Medicine in Hospice and Palliative Care: A Systematic Review. J

Pain Symptom Manage. 2018 Nov;56(5):781-794.e4. doi: 10.1016/j.jpainsymman.2018.07.016. Epub 2018 Aug 2. PMID: 30076965.

Moaleji, N. and Pangarkar, S. (2016, April). Oral Methadone Dosing Recommendations for the Treatment of Chronic Pain. Retrieved

from:

https://www.pbm.va.gov/PBM/clinicalguidance/clinicalrecommendations/Methadone_Dosing_Recommendations_for_the_Treatment_o

f_Chronic_Pain_July_2016.pdf

Habershaw, A. (2012, May). Methadone and QTc Prolongation. Retrieved from

https://www.urmc.rochester.edu/medialibraries/urmcmedia/medicine/palliativecare/patientcare/documents/methadoneandqtcprolong

ation.pdf

Reddy S, Hui D, El Osta B, et al. The Effect of Oral Methadone on the QTc Interval in Advanced Cancer Patients: A Prospective Pilot Study.

J Palliative Med. 2010;13:33-38.

Krantz MJ, Martin J, Stimmel B, et al. QTc Interval Screening in Methadone Treatment. Ann Intern Med. 2009;150:387-395.

Wong, E. (2013, January). A review of common methods to convert morphine to methadone. Retrieved from

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715153/

Osvaldo, Jose. (2015, March). Revisiting methadone: pharmacokinetics, pharmacodynamics and clinical indications. Retrieved from

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132015000100060

Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003;8:149-154.

End-Stage Respiratory Disease

By ProCare HospiceCare Team • September 13, 2024
End-Stage Respiratory Disease

Oropharyngeal Considerations at End of Life

March 20, 2024
Oropharyngeal Considerations at End of Life

Treatment of Insomnia at End of Life

March 20, 2024
Treatment of Insomnia at End of Life

Fatigue at End of Life

September 4, 2023
Fatigue is defined as a subjective feeling of tiredness, weakness, or lack of energy that can affect one’s physical, emotional, and cognitive state.

Symptom Management of End Stage Heart Disease

August 1, 2023
By Meri Madison, PharmD, RP

Strategies for Fall Prevention in Hospice/Palliative Care

By Meri Madison, PharmD, RPh • June 12, 2023
By 2030, 1 in 5 Americans will be aged 65 and older and we can anticipate 52 million falls and 12 million fall injuries.

Management of Oral Secretions and Congestion at End of Life

March 5, 2023
The presence of noisy respirations due to excessive secretions (also known as “gurgling” or “rattling”) at end of life predict a prognosis of days to weeks and can be alarming to family members.

The 12 Clinical Pearls of Symptom Management

By Meri Madison, PharmD, RPh • February 15, 2023
When managing symptoms at end of life, it can be a struggle to find the most appropriate medications.

Renal Impairment at End of Life: Dosing Implications for Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Antibiotics

October 21, 2022
Renal impairment is relatively common in both the elderly and hospice patients, and it can affect the way medications act in the body in several ways. Most commonly, it results in decreased clearance of renally-excreted medications, leading to accumulation of the drug and/or its metabolites and subsequent adverse or toxic effects. The absorption of oral medications may be reduced in patients with renal impairment due to increased gastric pH and gut wall edema. Uremia caused by renal impairment can increase sensitivity to medications that act on the central nervous system (CNS), as well as increase the risk of hyperkalemia due to potassium-sparing drugs. In addition, uremia can enhance the potential for NSAID-induced edema or GI bleeding. Renal impairment can also lead to edema or ascites, cachexia, dehydration, decreased albumin levels and binding capacity, and decreased tissue binding, all of which can impact the effects of medications. To compensate for these renal impairment-induced changes in drug disposition, the typical actions taken regarding medication administration are to decrease the dose, increase the dosing interval, or a combination of the two. The action that would be recommended depends on the drug and its specific characteristics. There are many medications that require dose adjustment in renal impairment, but here we’ll be discussing just those that are most often seen in hospice. The goal is to make you aware of these common medications (and categories) that often need dose adjustment so they trigger a mental alert for possible follow-up if they are ordered for your patients with decreased renal function. Opioids: Many opioids can accumulate in renal impairment as the parent drug and/or metabolites. Tramadol has a maximum daily dose in all patients, but in patients with a creatinine clearance (CrCL) less than 30 mL/minute, this maximum dose is reduced to 200 mg per day and the dosing interval should be extended to every 12 hours. Morphine renal dose reductions start with a CrCL less than 60 mL/minute, with possible extension of the dosing interval at this point as well. It is typically recommended to start considering alternatives to morphine in patients with a CrCL less than 30 mL/minute, and to avoid it altogether in patients with a CrCL less than 15 mL/minute. At end of life, the benefits of morphine can sometimes outweigh the risks. Because the presentation of renal accumulation-based adverse effects may be delayed, morphine can be used even in severe renal impairment or renal failure when the prognosis is hours to days, or in dialysis patients when death is imminent. Typically, oxycodone and hydromorphone are considered preferred alternatives to morphine in patients with significant renal impairment, although they both have metabolites that can accumulate in renal failure. As a result, the dose of oxycodone should be reduced and the dosing interval increased in patients with a CrCL less than 60 mL/minute, and oxycodone extended-release products should usually be avoided in patients with a CrCL less than 30 mL/minute. Hydromorphone dose reduction is also recommended when CrCL is less than 60 mL/minute; further dose reduction and extension of the dosing interval is recommended for hydromorphone when CrCL is less than 30 mL/minute. Although hydrocodone and its active metabolites may accumulate in renal impairment, there are no dose reductions for hydrocodone/acetaminophen according to the manufacturer’s labeling. Hydrocodone extended-release products (Hysingla ER®, Zohydro ER®) are rarely used in hospice, but dose reductions are recommended in patients with moderate to severe renal impairment. Methadone and fentanyl patch are considered among the safest opioids in renal impairment because they do not have active metabolites. However, renal impairment can still alter how fentanyl moves in the body, so dose reduction is recommended in patients with a CrCL of 50 mL/minute or less. For methadone, dose reduction is not recommended until very severe renal impairment (CrCL less than 10 mL/minute). No dose reductions are recommended for buprenorphine at any degree of renal impairment, and it is generally considered safe in this population. NSAIDs: Examples of NSAIDs that are commonly used in hospice include ibuprofen (Advil®, Motrin®), naproxen (Aleve®), and meloxicam (Mobic®), and as mentioned previously, there are some concerns regarding the use of NSAIDs in renal impairment. According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline, prolonged therapy with NSAIDs is not recommended if GFR is less than 60 mL/minute/1.73m² , and NSAIDs should typically be avoided in patients with a GFR less than 30 mL/minute/1.73m². As a general rule, NSAIDs should be used at the lowest effective dose for the shortest time possible in patients with renal impairment. In addition, NSAIDs should be avoided in patients with a high risk for developing acute kidney injury (e.g. volume depleted, elderly, and/or taking other nephrotoxic medications), and should be discontinued if acute kidney injury occurs during use. Antimicrobials: Many antimicrobials require dose reduction and/or extension of the dosing interval in renal impairment. Specific dosing recommendations depend on the antimicrobial in question and the type of infection being treated. When used for multiple doses, the dose of the antifungal fluconazole (Diflucan®) should be reduced in patients with a CrCL of 50 mL/minute or less. Examples of antibiotics commonly used in hospice that need dose adjustment include: sulfamethoxazole/trimethoprim (Bactrim®); fluoroquinolone antibiotics, including ciprofloxacin (Cipro®) and levofloxacin (Levaquin®); certain penicillin antibiotics, such as amoxicillin and amoxicillin/clavulanate (Augmentin®); and some cephalosporins, including cephalexin (Keflex®) and cefdinir (Omnicef®). Nitrofurantoin (Macrobid®, Macrodantin®) also has significant concerns in renal impairment. According to the manufacturer’s prescribing information, it is contraindicated in anuria, oliguria, or significant renal impairment (defined as a CrCL less than 60 mL/minute or clinically significant elevated serum creatinine). However, limited data suggest it is safe and effective for short-term use in patients with a CrCL of 30 to 60 mL/minute, although there appears to be an increased risk of pulmonary adverse events when eGFR is less than 50 mL/minute. In any case, nitrofurantoin should be avoided altogether in patients with a CrCL less than 30 mL/minute, due to the risk of pulmonary toxicity, hepatotoxicity, and peripheral neuropathy. Renal impairment can affect drug disposition in several ways, often increasing the risk of adverse and toxic effects. Whenever you have a patient with renal impairment, evaluate whether they are taking medications that may be cause for concern and require dose adjustment, and remember that hospice clinicians, pharmacists, and drug information resources can help by providing specific renal dosing recommendations. By Joelle K. Potts RPh, PharmD, BCGP REFERENCES: Aging and Kidney Disease. National Kidney Foundation. Available at: https://www.kidney.org/news/monthly/wkd_aging [accessed 8/8/2022] Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th American College of Physicians, Philadelphia, PA; 2007. Renal Impairment. Chapter in: Palliative Care Formulary, 7th Edition (PCF7). Wilcock A, Howard P, Charlesworth S, Eds. Pharmaceutical Press, London, UK. Chapter 17, added April 2017; 715-35. Drug monographs. Lexcomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc. https://online.lexi.com. O’Connor NR, Corcoran AM. End-stage renal disease: symptom management and advance care planning. Am Fam Physician. 2012; 85(7): 705-10. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. Jan 2013; 3(1). Available at: www.kidney-international.org Macrobid® Prescribing Information. Proctor and Gamble Pharmaceuticals, Inc. Cincinnati, OH. Revised Jan 2009. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf [accessed 6/13/2022] Macrodantin® Prescribing Information. Almatica Pharma Inc. Pine Brook, NJ. Revised Mar 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016620s072lbl.pdf [accessed 6/13/2022] 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated Beers Criteria® for potentially inappropriate medication use in older adults. JAGS. 2019; 00: 1-21

Buprenorphine for Pain Management: Pros vs. Cons in the Hospice Population

August 24, 2022
Buprenorphine is a unique opioid analgesic. It has several benefits (“pros”) for pain management, but it also has a few significant risks (“cons”) that prevent it from being used more frequently in hospice.  For pain management, buprenorphine is available as a buccal film (Belbuca®), a weekly transdermal patch (Butrans®), and an injection solution (Buprenex®). The forms that are most often seen in hospice patients are the buccal film and transdermal patch, which are used routinely as long-acting opioids for chronic pain, and these are the dosage forms we’ll be discussing here. Buprenorphine injection is indicated for acute pain and is not recommended for long-term use, and it is rarely used in hospice. Other dosage forms (monthly subcutaneous injection, 6-month subcutaneous implant, and daily sublingual tablet) are indicated for opioid use disorder and are not FDA-approved for pain management. What makes buprenorphine unique is the way it binds to various opioid receptors. The most commonly used opioid analgesics (e.g. morphine, oxycodone, fentanyl, and hydrocodone) are full mu-opioid receptor agonists, meaning they bind to and activate the mu-opioid receptor. In contrast, an antagonist blocks a receptor by binding to it without activating it; naloxone (Narcan®) is an excellent example of a mu-opioid receptor antagonist. Buprenorphine is a partial mu-opioid receptor agonist, which means that it binds to the mu-opioid receptor but activates it to a lesser degree than a full agonist. In addition to its effects at the mu-opioid receptor, buprenorphine has activity at three other opioid receptors: it is an antagonist at the delta- and kappa-opioid receptors, and a full agonist at the ORL-1 (opioid receptor-like 1; a.k.a. nociceptin) opioid receptor. The Pros of Buprenorphine: Effective for pain. Buprenorphine’s partial agonism at the mu-opioid receptor refers only to its activity level at the receptor, and not to its effectiveness as an analgesic. In fact, buprenorphine’s analgesic effects are comparable to full mu-opioid receptor agonists in a variety of different pain types, including moderate to severe post-operative and cancer pain, osteoarthritis, and chronic low back pain. Buprenorphine is also effective for neuropathic pain. Lower risk of certain opioid adverse effects. Because of buprenorphine’s unique activity at four opioid receptors, it is less likely to cause several common opioid adverse effects. When compared with most full mu-opioid receptor agonists, buprenorphine has a lower incidence of respiratory depression – although, as with all opioids, this adverse effect is still possible. Because buprenorphine is also less likely to produce euphoria, it has less potential for physical dependence and addiction; as such, it is classified as a Schedule III (C-III) controlled substance. In addition, when compared with the extended-release forms of oxycodone, hydromorphone, and oxymorphone, buprenorphine buccal film causes significantly less nausea, vomiting, constipation, dizziness, and somnolence. When buprenorphine is compared to morphine, the differences in adverse effect frequency are less pronounced, perhaps due to the dosage forms evaluated (or not evaluated). When comparing buprenorphine buccal film to morphine (dosage form not specified), buprenorphine appears to have just slightly lower incidences of constipation, somnolence, anxiety, and dry mouth. In a 2018 systematic review and meta-analysis of buprenorphine vs. morphine in acute pain management, the only significant difference in adverse effects identified was that buprenorphine was associated with less pruritis. The dosage forms considered in this review varied but were typically morphine injection vs. buprenorphine injection or sublingual tablet (not the patch or buccal film forms of buprenorphine that we usually see in our hospice patients). Safe in special populations. In addition, buprenorphine is considered safe in populations that we see often in hospice: those with renal impairment, including dialysis; those with mild to moderate hepatic impairment; and the elderly. The Cons of Buprenorphine: High cost. Unfortunately, buprenorphine patch and buccal film are relatively high-cost medications, which makes them much less attractive for use in hospice. Depending on the strength, the average cost for the generic weekly patch ranges from approximately $10 to $28 per day; the average cost for the brand buccal film, which is dosed once or twice a day, ranges from approximately $8 to $19 per film. Dosing limitations and cautions in severe hepatic impairment. A potential concern, especially in hospice patients, is that buprenorphine patch and buccal film both have maximum recommended doses. Also, the dose of the patch should be titrated no more frequently than every 72 hours, while the dose of the buccal film should be titrated no more frequently than every 4 days. Because buprenorphine has primarily hepatic metabolism, there are cautions regarding its use in severe liver impairment; in these patients, the dose of the buccal film should be reduced, and the transdermal patch form is not recommended. The Verdict: There are a number of reasons why buprenorphine patch and buccal film are excellent long-acting analgesics for many patients, especially those who are not approaching end of life. However, the cons can be significant, and buprenorphine is usually not preferred as a first- or second-line option for the majority of our hospice patients because other long-acting analgesics are effective and available at a much lower cost (e.g. methadone, morphine extended-release, and many strengths of fentanyl patch). In addition, the fact that buprenorphine patch and buccal film have maximum recommended doses may become an issue at end of life in patients whose pain is rapidly escalating. Of course, the pros and cons must always be weighed for each patient and their specific situation; no doubt there will be some hospice patients for whom buprenorphine patch or buccal film is an ideal choice. Written by Joelle Potts, PharmD, CGP REFERENCES: Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; July 23, 2022. https://online.lexi.com. [last accessed 7/23/2022] Buprenorphine Practitioner Resources and Information. Substance Abuse and Mental Health Services Administration (SAMSHA), U.S. Department of Health and Human Services. Programs: Medication-Assisted Treatment (MAT). Last updated 6/24/2021. Available at: https://www.samhsa.gov/medication-assisted-treatment/practitioner-resources [last accessed: 2/5/2022] Become a Buprenorphine Waivered Practitioner. Substance Abuse and Mental Health Services Administration (SAMSHA), U.S. Department of Health and Human Services. Programs: Medication-Assisted Treatment (MAT). Last updated 6/24/2021. Available at: https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner [last accessed: 2/5/2022] Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. U.S. Department of Health and Human Services, Federal Register document number 2021-08961, pages 22439-40; 4/28/2021. Available at: https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder [last accessed 2/5/2022] Pharmacist’s Manual: An Informational Outline of the Controlled Substances Act. EO-DEA154; revised 2020. Drug Enforcement Administration (DEA), Diversion Control Division. Available at: https://www.deadiversion.usdoj.gov/pubs/manuals/ [last accessed 2/28/2022] Pharmacological Treatment. Under: Opioids > Medication Assisted Recovery. Indian Health Service (IHS), Rockville, MD. https://www.ihs.gov/opioids/recovery/pharmatreatment/ [accessed 12/9/2021] Hale M, Garofoli M, Raffa RB. Benefit-risk analysis of buprenorphine for pain management. Journal of Pain Research, 2021:14; 1359-69. Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. Published online: 28 Jan 2020. Childers JW, Lou K, Arnold R. Fast Facts and Concepts #268. Low-dose buprenorphine patch for pain. October 2020. Available at: https://www.mypcnow.org Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. The Journal of Supportive Oncology. Nov-Dec 2012; 10(6): 209-19. Khanna IK, Pillarisetti S. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. Journal of Pain Research, 2015:8. 859-70. White LD, et al. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomized controlled trials. British Journal of Anaesthesia. 2018; 120(4): 668-78. Morphine (systemic). Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; July 20, 2022. https://online.lexi.com. [last accessed 7/23/2022] Butrans® (buprenorphine patch) prescribing information. Purdue Pharma LP, Stamford, CT. Revised March 2021. Available at: https://butrans.com [last accessed 3/15/2022] Belbuca® (buprenorphine buccal film) prescribing information. BioDelivery Sciences International, Inc., Raleigh, NC. Revised March 2021. Available at: https://www.belbuca.com. [last accessed 3/15/2022]
More Posts
Share by: